Legal Representation
Attorney
Ronald A. DiCerbo
USPTO Deadlines
Next Deadline
1655 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-02-13)
Due Date
February 13, 2030
Grace Period Ends
August 13, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
46 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 13, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Feb 13, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 9, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jan 8, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Dec 16, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Dec 15, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Dec 15, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Jun 30, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 30, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jun 30, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 30, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jun 30, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jun 23, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 22, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Jun 22, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jun 15, 2023 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Jun 15, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 17, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 15, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Dec 15, 2022 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Dec 15, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 17, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 15, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 15, 2022 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jun 15, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 17, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 15, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Dec 15, 2021 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Dec 15, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 17, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 15, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jun 15, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 15, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 15, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 20, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 20, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 30, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 15, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 14, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 14, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 14, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 13, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 13, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 13, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 6, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 13, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 042
Scientific research and development, namely, gene modification, including gene regulation and gene editing, for researching and developing modified mammalian and human cells and pharmaceuticals; research and development of therapeutics and pharmaceuticals using gene modification and gene editing technologies; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, gene modification, genome modification, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, gene modification, genome modification, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
First Use Anywhere:
20230500
First Use in Commerce:
20230500
Classification
International Classes
042